POPULARITY
Panel discussion and final remarks from Dr. Robert Lustig at the 2015 symposium. Series: "UCSF Consortium for Obesity Assessment, Study and Treatment" [Health and Medicine] [Science] [Education] [Professional Medical Education] [Show ID: 30504]
Panel discussion and final remarks from Dr. Robert Lustig at the 2015 symposium. Series: "UCSF Consortium for Obesity Assessment, Study and Treatment" [Health and Medicine] [Education] [Professional Medical Education] [Show ID: 30504]
Panel discussion and final remarks from Dr. Robert Lustig at the 2015 symposium. Series: "UCSF Consortium for Obesity Assessment, Study and Treatment" [Health and Medicine] [Science] [Education] [Professional Medical Education] [Show ID: 30504]
Panel discussion and final remarks from Dr. Robert Lustig at the 2015 symposium. Series: "UCSF Consortium for Obesity Assessment, Study and Treatment" [Health and Medicine] [Education] [Professional Medical Education] [Show ID: 30504]
COAST: UCSF Center for Obesity Assessment, Study and Treatment (Audio)
COAST: UCSF Center for Obesity Assessment, Study and Treatment (Video)
Dr. David Gerber, University of Texas-Southwestern, discusses the key results and potential implications of the CALGB 30504 trial of maintenance sunitinib for extensive stage SCLC.
Dr. David Gerber, University of Texas-Southwestern, discusses the key results and potential implications of the CALGB 30504 trial of maintenance sunitinib for extensive stage SCLC.
Dr. David Gerber, University of Texas-Southwestern, discusses the key results and potential implications of the CALGB 30504 trial of maintenance sunitinib for extensive stage SCLC.
Dr. David Gerber, University of Texas-Southwestern, discusses the key results and potential implications of the CALGB 30504 trial of maintenance sunitinib for extensive stage SCLC.
Dr. David Gerber, University of Texas-Southwestern, discusses the key results and potential implications of the CALGB 30504 trial of maintenance sunitinib for extensive stage SCLC.
Dr. David Gerber, University of Texas-Southwestern, discusses the key results and potential implications of the CALGB 30504 trial of maintenance sunitinib for extensive stage SCLC.